Business & Industry News Channel

Bristol Myers Squibb evolves and expands Standing in the Gaap to advance more equitable care in multiple myeloma

2026-04-16T10:00:00+02:00

Bristol Myers Squibb (NYSE: BMY), a global leader in oncology, announced the evolution of Standing in the Gaap, a long-running program designed to help address persistent gaps in care for people living with multiple myeloma (MM) in medically underserved communities. Building on a decade of sustained commitment, BMS is reinforcing its focus on equitable access to multiple myeloma education, resources, and community-driven solutions by expanding the program to reach more patients and care partners.

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

2026-04-08T10:00:00+02:00

Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform.

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

2026-03-18T10:00:00+01:00

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder.

Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'

2026-03-11T10:00:00+01:00

Abbott (NYSE: ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players aged 18-19 across the United States to sign up for the chance to take part in a once-in-a-lifetime development experience in Madrid. Selected participants will train with Real Madrid's world‑renowned coaches at the club's facilities and enjoy unique opportunities, including attending a Real Madrid match at the Bernabéu Stadium and meeting club legends.

Pfizer's Phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis

2026-03-09T10:00:00+01:00

Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥ 75% reduction in the Eczema Area and Severity Index) at Week 16, compared to placebo.

U.S. FDA grants full approval to Pfizer's BRAFTOVI combination regimen in first-line metastatic colorectal cancer

2026-02-24T10:00:00+01:00

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).

Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans

2026-02-11T10:00:00+01:00

Pfizer Inc. (NYSE: PFE) announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. The program provides Americans a wide range of more than 30 medicines at a significant discount off list prices.

Sanofi announces the signing of a share buyback mandate for up to €1 billion

2026-02-05T10:00:00+01:00

On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of €1 billion.

On February 2, 2026, Sanofi entered a mandate with an investment service provider for this program. Under the terms of the mandate, Sanofi will repurchase its own shares for a total consideration of up to €1 billion, between February 3, 2026, and December 31, 2026, at the latest(1).

AstraZeneca begins trading on the New York Stock Exchange

2026-02-02T10:00:00+01:00

AstraZeneca today begins trading its ordinary shares on the New York Stock Exchange (NYSE) for the first time, enabling more US investors to participate in the Company’s strong growth. With this change the trading of AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange (LSE) and Nasdaq Stockholm (STO) under a harmonised listing structure.

Abbott increases quarterly dividend for 54th consecutive year

2026-01-27T10:00:00+01:00

Abbott (NYSE: ABT) announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout has increased more than 70% since 2020.

This marks Abbott's 54th consecutive year of dividend growth and is the 408th consecutive quarterly dividend to be paid by Abbott since 1924.

Bristol Myers Squibb announces collaboration with Microsoft to advance AI-driven early detection of lung cancer

2026-01-21T10:00:00+01:00

Bristol Myers Squibb (NYSE: BMY, “BMS”), a global leader in oncology, announced an agreement with Microsoft, a market leader in AI-powered radiology and clinical workflow technologies, aiming to accelerate early detection of lung cancer.

Through this digital health collaboration, U.S. FDA-cleared radiology AI algorithms will be deployed via Microsoft’s Precision Imaging Network, part of Microsoft for Healthcare radiology solutions.

Merck to complete acquisition of Cidara Therapeutics

2026-01-13T10:00:00+01:00

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”).

Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization

2026-01-07T10:00:00+01:00

Bayer and Cradle have entered a three-year strategic collaboration to deploy Cradle’s scientific AI software platform for protein engineering. As part of the collaboration, Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline.

Pfizer files lawsuit against Metsera and its directors and Novo Nordisk for breach of merger agreement

2025-10-31T12:00:00+01:00

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreement between Pfizer and Metsera.